FDA Approval: Economics, Not Science? Unpacking the System FDA to weigh easing limits on unproven peptides The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides promoted by RFK Jr.